Evidence map›Paper›PMID 40595576›Full record

ArticleNature communications2025

In-host evolution of Yersinia enterocolitica during a chronic human infection.

Cyril Savin, Pierre Lê-Bury, Julien Guglielmini, Thibaut Douché, Guillem Mas Fiol, Rodolphe Buzelé, Cécile Le Brun, Frédéric Bastides, Maud François, Béatrice Birmelé and 10 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Anti-infective compounds forSustainable microbiology · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Cyril Savin *Institut Pasteur, Université Paris Cité, Yersinia Research Unit, Paris, France. cyril.savin@pasteur.fr.ORCID http://orcid.org/0000-0003-2659-3433
Pierre Lê-Bury *Institut Pasteur, Université Paris Cité, Yersinia Research Unit, Paris, France.ORCID http://orcid.org/0000-0002-6010-2952
Julien GuglielminiInstitut Pasteur, Université Paris Cité, CNRS USR 3756, Biostatistics and Bioinformatics Hub, Paris, France.ORCID http://orcid.org/0000-0002-8566-1726
Thibaut DouchéInstitut Pasteur, Université Paris Cité, CNRS UAR2024, Proteomic Platform, Mass Spectrometry for Biology Unit, Paris, France.ORCID http://orcid.org/0000-0001-8627-6726
Guillem Mas FiolInstitut Pasteur, Université Paris Cité, Yersinia Research Unit, Paris, France.ORCID http://orcid.org/0000-0002-4024-3002
Rodolphe BuzeléService de Bactériologie-Virologie, CHRU de Tours, Tours, France.
Cécile Le BrunService de Bactériologie-Virologie, CHRU de Tours, Tours, France.ORCID http://orcid.org/0000-0002-9846-0210
Frédéric BastidesService de Médecine Interne et des Maladies Infectieuses, CHRU de Tours, Tours, France.
Maud FrançoisService d'Hémodialyse, CHRU de Tours, Tours, France.
Béatrice BirmeléService d'Hémodialyse, CHRU de Tours, Tours, France.
Laura GuichardInstitut Pasteur, Université Paris Cité, Yersinia Research Unit, Paris, France.
Julien MadejInstitut Pasteur, Université Paris Cité, Yersinia Research Unit, Paris, France.
Rémi BeauInstitut Pasteur, Université Paris Cité, Yersinia Research Unit, Paris, France.
Nicolas CabanelInstitut Pasteur, Université Paris Cité, Yersinia Research Unit, Paris, France.
Laurent DortetUniversité Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT/UMRS1184), Fontenay-aux-Roses & Le Kremlin-Bicêtre, France.ORCID http://orcid.org/0000-0001-6596-7384
Mariette MatondoInstitut Pasteur, Université Paris Cité, CNRS UAR2024, Proteomic Platform, Mass Spectrometry for Biology Unit, Paris, France.ORCID http://orcid.org/0000-0003-3958-7710
Olivier DussurgetInstitut Pasteur, Université Paris Cité, Yersinia Research Unit, Paris, France.ORCID http://orcid.org/0000-0001-9924-0837
Elisabeth CarnielInstitut Pasteur, Université Paris Cité, Yersinia Research Unit, Paris, France.
Philippe LanotteService de Bactériologie-Virologie, CHRU de Tours, Tours, France.ORCID http://orcid.org/0000-0002-9993-5548
Javier Pizarro-CerdáInstitut Pasteur, Université Paris Cité, Yersinia Research Unit, Paris, France. javier.pizarro-cerda@pasteur.fr.ORCID http://orcid.org/0000-0002-4343-0508

Funding

Agence Nationale de la Recherche (French National Research Agency) ANR-10LBX-62-IBEIDAgence Nationale de la Recherche (French National Research Agency) ANR-16-CONV-0005Fondation pour la Recherche Médicale (Foundation for Medical Research in France) FDT20220401-711 5222
6 · The paper itself

Abstract

Bacteria exhibit remarkable adaptability in response to selective pressures encountered during infection and antibiotic treatment. We characterize four Yersinia enterocolitica clonal isolates from successive bacteremia episodes that evolved within an elderly patient over 14 years. Their common evolution is characterized by a genome size reduction resulting in the loss of about a hundred genes and a so far undescribed deletion in the DNA gyrase gene gyrA conferring quinolone resistance. Third-generation cephalosporin resistance of the last isolate correlates with a truncation of OmpF in synergy with an increased production of BlaA and AmpC β-lactamases. A strong proteome remodeling of the isolates reveals a perturbed stringent response, as well as impaired metabolism which substantiate their severe growth defects in vitro, accounting for antibiotics tolerance and possibly therapeutic failure. This study documents previously unreported genetic and phenotypic changes associated with in-host adaptation of a pathogenic Yersinia species under antibiotic pressure.

Indexed as

Yersinia enterocoliticaYersinia InfectionsAgedAnti-Bacterial AgentsBacteremiaBacterial Proteinsbeta-LactamasesChronic DiseaseDNA GyraseDrug Resistance, BacterialEvolution, MolecularGenome, BacterialHumansMicrobial Sensitivity TestsAmpC beta-lactamasesAnti-Bacterial AgentsBacterial Proteinsbeta-LactamasesDNA Gyrase

Identifiers

PMID40595576
PMCPMC12218051

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.